Gland Pharma Ltd vs Ipca Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Gland Pharma Ltd is ₹ 1773 as of 05 May 15:30 . The P/E Ratio of Gland Pharma Ltd changed from 40.7 on March 2021 to 37.5 on March 2025 . This represents a CAGR of -1.62% over 5 yearsThe P/E Ratio of Ipca Laboratories Ltd changed from 21.2 on March 2021 to 51.6 on March 2025 . This represents a CAGR of 19.47% over 5 years The Market Cap of Gland Pharma Ltd changed from ₹ 40535 crore on March 2021 to ₹ 26232 crore on March 2025 . This represents a CAGR of -8.34% over 5 yearsThe Market Cap of Ipca Laboratories Ltd changed from ₹ 24137 crore on March 2021 to ₹ 38088 crore on March 2025 . This represents a CAGR of 9.55% over 5 years The revenue of Gland Pharma Ltd for the Dec '25 is ₹ 1758 crore as compare to the Sep '25 revenue of ₹ 1571 crore. This represent the growth of 11.93% The revenue of Ipca Laboratories Ltd for the Dec '25 is ₹ 2430 crore as compare to the Sep '25 revenue of ₹ 2584 crore. This represent the decline of -5.96% The ebitda of Gland Pharma Ltd for the Dec '25 is ₹ 473.7 crore as compare to the Sep '25 ebitda of ₹ 398.05 crore. This represent the growth of 19.01% The ebitda of Ipca Laboratories Ltd for the Dec '25 is ₹ 571.19 crore as compare to the Sep '25 ebitda of ₹ 514.52 crore. This represent the growth of 11.01% The net profit of Gland Pharma Ltd changed from ₹ 143.76 crore to ₹ 261.48 crore over 7 quarters. This represents a CAGR of 40.75% The net profit of Ipca Laboratories Ltd changed from ₹ 198.98 crore to ₹ 364.05 crore over 7 quarters. This represents a CAGR of 41.23% The Dividend Payout of Gland Pharma Ltd changed from 31.57 % on March 2024 to 27.22 % on March 2025 . This represents a CAGR of -7.14% over 2 yearsThe Dividend Payout of Ipca Laboratories Ltd changed from 8.9 % on March 2021 to 15.59 % on March 2025 . This represents a CAGR of 11.86% over 5 years .

About Gland Pharma Ltd

Gland Pharma Limited was incorporated as Gland Pharma Private Limited', a private limited company on March 20, 1978 and was granted the certificate of incorporation by Registrar of Companies, Andhra Pradesh at Hyderabad.
Subsequently, the name of the Company was changed to Gland Pharma Limited' and a fresh certificate of incorporation dated April 25, 1995 was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad.
The Company is primarily engaged in manufacturing injectable formulations. Established in Hyderabad, India, Company has evolved into a prominent entity in the global generic injectables market, with operations extending to over 60 countries including the United States, Europe, Canada, Australia, and India.
Primarily functioning under a B2B model, the company provides comprehensive services such as contract development, dossier compilation, technology transfer, and manufacturing across various delivery systems.

About Ipca Laboratories Ltd

Ipca Laboratories Limited (IPCA) was incorporated on 19 October, 1949 under the name of 'The Indian Pharmaceutical Combine Association Limited.' Ipca is a fully integrated, pharmaceutical company manufacturing and marketing over 350 formulations and 80 API's covering various therapeutic segments.
The products of the Company are now sold in over 100 countries across the globe.
The Company has 18 manufacturing units in India manufacturing API's and formulations for the world market. Ipca's APIs and Formulations produced at world class manufacturing facilities are approved by leading drug regulatory authorities including the US-Food and Drug Administration (FDA), UK-Medicines and Healthcare products Regulatory Agency (MHRA), South Africa-Medicines Control Council (MCC), Brazil-Brazilian National Health Vigilance Agency (ANVISA) and Australia-Therapeutic Goods Administration (TGA) with operations in over 100 countries.

FAQs for the comparison of Gland Pharma Ltd and Ipca Laboratories Ltd

Which company has a larger market capitalization, Gland Pharma Ltd or Ipca Laboratories Ltd?

Market cap of Gland Pharma Ltd is 29,941 Cr while Market cap of Ipca Laboratories Ltd is 38,831 Cr

What are the key factors driving the stock performance of Gland Pharma Ltd and Ipca Laboratories Ltd?

The stock performance of Gland Pharma Ltd and Ipca Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gland Pharma Ltd and Ipca Laboratories Ltd?

As of May 5, 2026, the Gland Pharma Ltd stock price is INR ₹1817.3. On the other hand, Ipca Laboratories Ltd stock price is INR ₹1530.6.

How do dividend payouts of Gland Pharma Ltd and Ipca Laboratories Ltd compare?

To compare the dividend payouts of Gland Pharma Ltd and Ipca Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.